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Abstract Medulloblastoma is the most common malig-
nant brain tumor of childhood. Despite numerous advances,
clinical challenges range from recurrent and progressive
disease to long-term toxicities in survivors. The lack of
more effective, less toxic therapies results from our limited
understanding of medulloblastoma growth. Although TP53
is the most commonly altered gene in cancers, it is rarely
mutated in medulloblastoma. Accumulating evidence,
however, indicates that TP53 pathways are disrupted in
medulloblastoma. Wild-type p53-induced phosphatase 1
(WIP1 or PPM1D) encodes a negative regulator of p53.
WIP1 amplification (17q22-q23) and its overexpression
have been reported in diverse cancer types. We examined
primary medulloblastoma specimens and cell lines, and
detected WIP1 copy gain and amplification prevalent
among but not exclusively in the tumors with 17q gain and
isochromosome 17q (i17q), which are among the most
common cytogenetic lesions in medulloblastoma. WIP1
RNA levels were significantly higher in the tumors with
17q gain or i17q. Immunoblots confirmed significant WIP1
protein in primary tumors, generally higher in those with
17q gain or i17q. Under basal growth conditions and in
response to the chemotherapeutic agent, etoposide, WIP1
antagonized p53-mediated apoptosis in medulloblastoma
cell lines. These results indicate that medulloblastoma
express significant levels of WIP1 that modulate genotoxic
responsiveness by negatively regulating p53.
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Introduction
Medulloblastoma is the most common malignant brain
tumor of childhood [1, 2]. Treatment with surgery, radia-
tion, and chemotherapy successfully cures many patients,
but survivors can suffer significant long-term toxicities
affecting their neurocognitive and growth potential [3].
Despite clinical advances, up to 30% of children with
medulloblastoma experience tumor progression or recur-
rence, for which no curative therapy exists. The lack of
more effective, less toxic therapies stems from our
imperfect understanding of the molecular processes that
underlie medulloblastoma growth.
Among the most common cytogenetic lesions affecting
medulloblastoma are the gain of the long arm of chromo-
some 17 (17q) and isochromosome 17q (i17q), consisting
of 17p deletion with duplication of 17q, in approximately
one-third of cases [4, 5]. Because i17q has been described
as the sole cytogenetic lesion in certain medulloblastomas,
it may represent a primary event rather than an alteration
associated with clonal evolution [4]. Investigators have
long sought oncogenes on 17q and tumor suppressor genes
on 17p, but with limited success [6].
Although the TP53 tumor suppressor gene (17p13.1) is
mutated in approximately half of human malignancies, it is
rarely mutated in medulloblastoma [7–9]. However, sev-
eral lines of evidence suggest that the p53 pathway is
perturbed in medulloblastoma. Frank et al. have described
activation of the p53-p14ARF pathway in the large
cell/anaplastic variant of medulloblastoma [10, 11]. Our
collaborators have noted significant nuclear p53 immu-
nopositivity consistent with its activation in approximately
50% of primary human medulloblastoma examined (Ade-
kunle Adesina, personal communication). Deletion of the
murine homolog, Trp53, in the Patched haploinsufficient
(Ptch+/–) mouse model increases the incidence of spon-
taneous medulloblastoma from approximately 15 to 100%
[12]. Individuals with Li–Fraumeni syndrome who carry
germline TP53 mutations are at increased risk for devel-
oping medulloblastoma, but fewer than 10% of sporadic
medulloblastoma display TP53 mutations [4, 5].
The activity of p53 may be abrogated by alternate
mechanisms as observed in other cancers with wild-type
TP53 [7]. One mechanism by which p53 function is limited
is through amplification or overexpression of MDM2.
MDM2 encodes an E3 ubiquitin ligase that normally
functions in a negative feedback loop to down-regulate p53
expression, and is amplified in approximately 7% of human
malignancies that lack mutation of TP53 [13]. However,
Adesina et al. and Batra et al. have documented the
absence of MDM2 amplification in medullobastoma [14,
15]. Although MDM2 overexpression has been detected in
adult patients [16], there is no functional data to implicate
MDM2 in p53 inactivation in medulloblastoma, suggesting
alternative mechanisms.
The p53-induced proto-oncogene, WIP1 (wild-type p53-
induced phosphatase 1 or protein phosphatase, magne-
sium-dependent 1, delta, PPM1D) maps to 17q22-q23.
Amplification of 17q22-q23 has been described in several
cell lines and malignancies including neuroblastoma, breast
and ovarian carcinomas, most of which are wild-type for
TP53 [17–19]. WIP1 displays p53-dependent oncogenic
properties by inactivating p53, p38MAPK, and ATM
pathways [17–21]. Previous reports of genomic analysis of
medulloblastoma have implicated the gain of the WIP1
locus in its overexpression in a subset of tumors [22, 23].
We present data that confirm prior observations and also
define the effects of WIP1 on medulloblastoma cell growth.
We have quantitated WIP1 overexpression in primary
medulloblastoma specimens and cell lines previously ana-
lyzed by comparative genomic hybridization (CGH) [24].
Using fluorescence in situ hybridization (FISH), we
determined that WIP1 copy gain and amplification is pre-
valent among but not exclusively found in the tumors with
17q gain and i17q. We surveyed 33 primary medulloblas-
toma specimens for WIP1 expression and determined that
RNA levels were significantly higher in 16 tumors with
17q gain or i17q. Similarly, our Western immunoblot
analysis confirmed significant levels of WIP1 protein
expression in primary tumors, generally higher in those
with 17q gain or i17q. Genotoxic stress induces p53
phosphorylation and WIP1 expression in D283Med and
Daoy medulloblastoma cell lines. Transient transfections
indicate that WIP1 antagonizes p53-mediated cell cycle
arrest and apoptosis in response to the chemotherapeutic
agent, etoposide. These results support the hypothesis that
medulloblastoma express significant levels of WIP1 that
modulate genotoxic responsiveness by negatively regulat-
ing p53.
Materials and methods
Medulloblastoma tissue and cell lines
Medulloblastoma samples (n = 33) were obtained from
children diagnosed at Texas Children’s Hospital, Houston,
TX, between 1996 and 2004, following informed consents.
246 J Neurooncol (2008) 86:245–256
123
Tissues were snap-frozen and stored in liquid nitrogen until
processed. All specimens were obtained at the time of
diagnosis prior to radiation or chemotherapy and subjected
to histopathologic review according to WHO criteria [1].
Seven tumors displayed classic histology, 11 were uni-
formly desmoplastic, nodular, or well-differentiated, seven
were predominantly anaplastic or large cell, an additional
seven displayed some degree of anaplasia or large cell
histology, and one was regarded as none of the above.
Ten patients were female and 23 were male. The mean
age at diagnosis was 82 months (median 79 months) with
four patients less than 36 months old (range: 12–
216 months). The median and mean time of follow-up was
approximately 42 months from diagnosis. The majority of
patients were M0 (non-metastatic), while one was M2 and
eight were M3 stage at diagnosis. All studies were per-
formed according to the institutional guidelines of Texas
Children’s Hospital, and with the approval of the Institu-
tional Review Board of Baylor College of Medicine.
The breast carcinoma cell line MCF-7 with known high-
level WIP1 amplification, the un-amplified breast epithelial
cell line MCF-10A, and the medulloblastoma cell lines,
Daoy and D283Med (American Type Culture Collection,
Manassas, VA) were maintained as previously described in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carls-
bad, CA) with high glucose (6 g/l), 2 mM L-glutamine and
10% (vol/vol) heat-inactivated fetal calf serum (Invitrogen,
Carlsbad, CA) at 37C in 5% CO2. Etoposide (VP-16) and
cisplatin (CDDP) were applied to cell cultures as media-
diluted stock solutions in PBS and DMSO, respectively
(Sigma, St. Louis, MO). Ultraviolet (UV) irradiation was
performed by exposing cell cultures using a GS Gene Lin-
ker UV Chamber (Bio-Rad Laboratories, Hercules, CA).
Fluorescence in situ hybridization (FISH) analysis
Primary medulloblastoma cells were harvested from first
passage cultures. Chromosomes were prepared according
to standard methods, including confirmatory karyotyping
with G-banding [25]. Eleven first or second passage cul-
tures of primary tumors were harvested when cultures were
still sub-confluent. The BAC containing the WIP1 locus at
chromosome 17q23 (RP11-67D12) and a plasmid con-
taining chromosome 17 centromeric sequences (pZ17-14,
generously provided by Dr. Mariano Rocchi) were fluo-
rescently labeled with Spectrum Green and Spectrum
Orange, respectively (Vysis, Downers Grove, IL), by nick
translation and hybridized to metaphase or interphase
spreads of cell lines (MCF-7, Daoy, D283) and primary
tumor specimens [26]. We confirmed the map position of
WIP1 on normal human metaphase spreads by FISH, as
described previously [27]. The slides were counterstained
with DAPI, and the images were captured using the Quips
Pathvysion System (Applied Imaging, Santa Clara, CA).
To determine the WIP1 copy number status, we analyzed
100–200 individual interphase nuclei for each case. The
presence of copy gain or amplification was indicated if
more than 10% of tumor nuclei displayed an increased
copy number relative to the chromosome 17 centromeric
probe signals and/or tumor ploidy. In cases in which there
was a discrepancy between the number of centromeric
signals and ploidy, the ploidy number was used to estimate
the relative copy number.
Quantitative real-time RT-PCR (qRT-RTPCR) analysis
Total cellular RNA was prepared from frozen tumor tissue
with either Trizol (Invitrogen) or an RNeasy kit (Qiagen,
Valencia, CA) depending upon relative abundance,
according to the manufacturers’ recommendations. Integ-
rity and concentration of RNA were verified on the Baylor
College of Medicine, Houston, TX Microarray Core
Facility Bioanalyzer (Agilent Technologies, Santa Clara,
CA). Total cellular RNA was reverse transcribed with
SuperScript First-Strand Synthesis (Invitrogen) primed with
oligo-(dT)12. PCR reactions were performed in a Bio-Rad
iCycler using iQ Syber Green Supermix (Bio-Rad Labora-
tories), and primers listed below. Each PCR reaction was
performed for 40 cycles, and performed in triplicate. Primer
sequences included: WIP1 sense, 50-ATCCGCAAAGG-
CTTTCTCGCTT-30 and antisense, 50-TTGGCCATTCC
GCCAGTTTCTT-30; TP53 sense, 50-CCATCTACAAGCA
GTCACAGC-30 and antisense, 50-GAGTCTTCCAGTG
TGAGATG-30; GAPDH sense, 50-AAGGTGAAGGTCG-
GAGTCAA-30 and antisense, 50-AATGAAGGGGTCAT
TGATGG-30. Expression of target RNA was internally
normalized to expression of GAPDH gene and expressed
relative to target gene expression in a human fetal brain
RNA pool (Stratagene, La Jolla, CA). Human adult cere-
bellar (Stratagene) and human fetal cerebellar RNA samples
(BioChain, Hayward, CA) were also assayed to provide
tissue controls. Amplification products were verified by
analyzing melting curves, agarose gel electrophoresis, and
with direct sequencing of PCR products.
Western immunoblot analysis
Protein was extracted from frozen tissue by solubilization
in boiling lysis buffer (0.5% SDS, 50 mM Tris–Cl, pH 8,
5 mM Na2EDTA, 2% b-mercaptoethanol). Lysates were
stored at –80C and separated by SDS-PAGE, transferred
to nitrocellulose membranes (Pall Life Sciences, Ann
Arbor, MI), and immunoblotted using standard methods.
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Primary antibodies included: WIP1 monoclonal antibody
(Trevigen, Gaithersburg, MD), Phospho-p53 serine-15
(Ser15)-specific monoclonal antibody (Cell Signaling
Technology, Danvers, MA), p53 monoclonal antibody
(DO-1, Santa Cruz Biotechnology, Santa Cruz, CA), and b-
Actin monoclonal antibody (Sigma). Staining with sec-
ondary antibody (Alexa Fluor 680-nm-conjugated goat
anti-mouse IgG, Invitrogen) was visualized using an
Odyssey infrared imaging system (LI-COR Biosciences,
Lincoln, Nebraska). Intensity of immunostaining was
quantitated using ImageQuant 5.2 (Molecular Dynamics,
Piscataway, NJ). Expression of target proteins in each
sample was internally normalized to b-actin (determined
on re-probed blots), relative to expression in the MCF-10A
cell line.
Transfections and luciferase reporter assays
Cell lines were transiently transfected with expression and
reporter plasmids using Lipofectin according to manufac-
turer’s recommendations (Invitrogen). Expression plasmids
included: the human cytomegalovirus (CMV) immediate-
early (IE) promoter-driven pP53-EGFP plasmid, encoding
a p53-enhanced green fluorescent protein (GFP) fusion
protein (Clontech, Mountainview, CA). Reporter plasmids
included the pP21-luciferase construct to detect p53-acti-
vated transcription [28] and the actin promoter-driven
Renilla luciferase plasmid, pB-Actin-RL, to provide
transfection controls [29]. In each transfection, the
expression and reporter plasmids were supplemented by
empty vector plasmid (pcDNA3.1, Invitrogen) to achieve
an equivalent total DNA concentration.
For flow cytometry, the EGFP-expressing pMaxGFP
plasmid (Amaxa, Gaithersburg, MD) provided transfection
controls. For functional assessment of in vitro p53 activa-
tion, cells transfected with luciferase-encoding reporter
plasmids were harvested and processed for dual color
luciferase assay according to manufacturer’s recommen-
dations (Promega, Madison, WI), and quantitated using a
BenchMark Plus plate spectrophotometer (Bio-Rad).
Flow cytometric and terminal deoxynucleotidyl
transferase-mediated biotinylated-dUTP nick end-
labeling (TUNEL) analysis
We monitored DNA-indices for cell cycle analysis by
multi-parametric flow cytometry using standard methods.
Analyses were performed using a Becton Dickinson
FACScan flow cytometer (BD Biosciences, San Jose, CA)
for the detection of cells stained with propidium iodide (PI)
and a 488 nm laser with filter combination for fluorescein
isothiocyanate (FITC) and GFP. Single cell suspensions
were isolated from culture, fixed in methanol, and stained
with PI (100 lg/ml in PBS). Each histogram represents
10,000–100,000 cells for measuring DNA-index and cell
cycle. Histogram analysis was performed with the CellQuest
program (BD Biosciences). We calculated the sub-G0/G1
peak at a position in the hypodiploid area below a DNA-
index of one (2n). Because the nucleus becomes fragmented
during apoptosis and numerous individual chromatin frag-
ments may be present in a single cell, the percentage of
objects with a fractional DNA-content is represented by the
sub-G0/G1 peak. Apoptotic nuclei were identified as a sub-
diploid DNA peak, and were distinguished from cell debris
on the basis of forward light scatter and PI fluorescence. The
significance of differences in apoptotic populations was
determined using paired Student t-test.
To detect apoptotic nuclei in sub-G0/G1 peaks, a subset
of unstained cells was analyzed for DNA-fragmentation
using the Frag-EL DNA fragmentation detection kit,
according to manufacturer’s recommendations (Oncogene
Research Products, Cambridge, MA). Cells were also
counter-stained with PI for DNA quantification. FITC sig-
nal was detected on one channel in the logarithmic mode,
while UV fluorescence (PI) was recorded in the linear mode
on a separate channel. For each measurement, at least
10,000 cells were analyzed. We used CellQuest software
for multi-parametric calculations and analyses. Cutoff
negative and positive cells resulted from FITC-fluorescence
isotype control measurements for each sample.
Results
WIP1 DNA copy number is increased
in medulloblastomas with 17q gain
We employed FISH to analyze copy numbers of the WIP1
gene in primary medulloblastoma specimens and cell lines
previously analyzed by CGH (Fig. 1). Compared to the
centromeric chromosome 17 probe, which consistently
displayed 2–4 signals in each metaphase or interphase
nucleus, the 17q23 BAC probe (RP11-67D12) containing
the WIP1 locus revealed a wider range of copy numbers.
By FISH, we identified high-level amplification of the
WIP1 gene ([50 copies/cell) in all of the MCF-7 cells
analyzed (Fig. 1A). This finding is consistent with previ-
ously identified amplification of the 17q23 chromosomal
region in MCF-7 cells. The D283Med (D283) medullo-
blastoma cell line, with i17q, displayed low-level
amplification of the WIP1 locus with four to nine copies in
each interphase spread examined (Fig. 1B). In contrast, the
Daoy medulloblastoma cell line with trisomy 17 displayed
an average of three copies of WIP1 (Fig. 1C).
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Among the 71 tumors analyzed by CGH, 11 primary
medulloblastomas were examined for WIP1 amplification
by FISH [24]. Six tumors displayed i17q, two showed tri-
somy 17, one had loss of 17p12-p13 with gain of 17p11.2-
q25, and two had no change in chromosome 17 (Table 1).
We detected low-level amplification of the WIP1 locus in 7
of 11 primary medulloblastoma specimens, which also had
gain of 17q, including four with i17q by G-banding.
Four tumors were diploid or near-diploid overall
(Fig. 1D–G), and seven displayed copy number gain of the
WIP1 locus (Fig. 1H–L). Our previously reported CGH
analysis of 71 medulloblastoma revealed that 46.8% had
gain of 17q, including 30% with i17q and 2.6% with
amplifications involving 17q, consistent with previous
reports [4]. Comparing CGH results with our FISH analysis
reveals that WIP1 DNA copy number correlates with gain
of 17q (including i17q) by CGH (P \ 0.001, Student’s t-
test). All the tumors with copy number gain of WIP1 by
FISH also had gain of the WIP1 locus on chromosome
17q22-q23 by CGH. WIP1 amplification in medulloblas-
toma was low-level compared to the high-level
amplification observed in MCF-7 cells. These cytogenetic
results indicate that low-level amplification of the WIP1
locus are prevalent in a significant proportion of
medulloblastoma.
Medulloblastomas with gain of 17q, including i17q,
overexpress WIP1 RNA
Using qRT-RTPCR, we determined the expression of
WIP1 RNA in cell lines and a larger series of primary
medulloblastoma samples. Human fetal cerebellum speci-
mens displayed 2.1-fold greater WIP1 expression (±0.2,
SEM) compared to fetal whole brain. Human adult cere-
bellum expresses 4.0-fold more WIP1 RNA (±1.0) than
fetal total brain. WIP1-amplified MCF-7 cells had 14-fold
higher levels of WIP1 RNA (±2.6), relative to human fetal
brain (Fig. 2A). Daoy cells expressed 0.23-fold WIP1 RNA
(±0.054, SEM), compared to fetal brain (Fig. 2A). In
contrast, i17q-positive D283 cells displayed 9.8-fold (±1.8)
higher expression of WIP1 RNA than human fetal brain.
We surveyed 33 primary medulloblastoma specimens
for WIP1 expression and determined that RNA levels were
significantly higher in 16 tumors with 17q gain or i17q
(Fig. 2, Table 2). Of the primary medulloblastomas
examined by FISH, WIP1-amplified tumors (n = 7) dis-
played significantly higher RNA levels than non-amplified
tumors (n = 4) (27.7-fold (±1.6) vs. 14.1-fold (±4.5) more
WIP1 RNA than fetal control; P = 0.050) (Fig. 2C,
Table 2). Among the larger set of analyzed specimens,
primary medulloblastoma samples displayed 13.0-fold
Fig. 1 WIP1 copy number is increased in medulloblastomas with
gain of chromosome 17q. High power micrographs of interphase
nuclei of cell lines and primary human medulloblastoma cells
hybridized to fluorescently-labeled WIP1 BAC (green) and centro-
meric chromosome 17 probes (red): (A) MCF-7 nucleus showing
numerous WIP1 amplicons; (B) D283Med (D283) nucleus exhibiting
low-level WIP1 amplification; (C) Daoy nucleus showing gain of 17;
(D–L) interphase nuclei of medulloblastoma cells from nine patients,
illustrating examples of (D–H) diploid and near-diploid nuclei, and
(I–L) those with low-level amplification of WIP1
J Neurooncol (2008) 86:245–256 249
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higher levels of WIP1 RNA (±2.1) than human fetal brain
(Fig. 2A–B, Table 2). Analyzed separately, tumors with
gain of 17q, including i17q, (n = 16) expressed 20.3-fold
more WIP1 RNA (±2.1), compared to those without gain of
17q or i17q (n = 17) with only 5.9-fold more WIP1 RNA
(±1.0), relative to human fetal brain (Fig. 2A–B, Table 2).
In other words, those tumors with gain of 17q, including
i17q, expressed 3.4-fold more WIP1 RNA (±0.86) than
those without such cytogenetic lesions. The association
between WIP1 RNA expression and the presence or
absence of 17q gain (including i17q) was statistically sig-
nificant (P \ 0.00001) (Table 2).
Medulloblastomas with gain of 17q overexpress WIP1
protein
A subset of representative tumors with sufficient tissue was
analyzed for WIP1 protein expression. Western immunoblot
analysis confirmed significant protein expression in lysates
from medulloblastoma cell lines and tumor samples, inter-
nally normalized to b-actin expression and relative to
expression in the MCF-10A cell line (Fig. 3A–B). The
medulloblastoma cell line, Daoy, with trisomy 17, expressed
3.1-fold more WIP1 protein (±0.5, SEM) than MCF-10A cells
(Fig. 3A–B). The D283 cell line, with i17q, displayed 15.4-
fold higher WIP1 levels (±2.0) than MCF-10A (Fig. 3A–B).
Since UV irradiation activates p53 by phosphorylation at
serine 15 and induces WIP1 expression [30], we used lysates
prepared from irradiated D283 cells to provide control spec-
imens with induced p53 and WIP1 proteins. In UV-irradiated
D283 cells, p53 levels stabilized with increased phosphory-
lation at Ser15 (Fig. 3A). The WIP1-amplified breast cancer
line, MCF-7, expressed 4.5-fold more WIP1 (±0.4) than MCF-
10A cells (Fig. 3A–B).
Of the ten primary medulloblastoma specimens ana-
lyzed, five displayed gain of 17q or i17q, one had trisomy
17, another had loss of 17p, and three showed no change in
chromosome 17 by CGH. Overall, mean WIP1 protein
expression was 6.1-fold (±1.1) greater than expression in
MCF-10A cells, internally normalized to b-actin (Fig. 3B).
As a group, primary tumors exhibited even more WIP1
than the MCF-7 cell line, which is widely employed as an
example of WIP1-amplification. Analyzed separately, pri-
mary medulloblastomas with 17q or i17q (n = 6) displayed
7.1-fold (±1.5) more WIP1 protein than MCF-10A, com-
pared to non-17q gain tumors (n = 4) with only 4.6-fold
(±1.3) levels (Fig. 3B). We also analyzed primary medul-
loblastoma lysates for expression of total p53 protein and
p53 phosphorylation at serine 15 (Ser15) (Fig. 3). Total
p53 and phospho-p53 (Ser15) were readily detectable on
Western blots, and suggest functional significance. Overall,
Western analysis indicated significant levels of WIP1
protein expression in primary tumors, generally higher in
those with 17q gain or i17q, which might be responsible for
antagonizing p53 activation.
Genotoxic stress induces p53 phosphorylation
and WIP1 expression in medulloblastoma cell lines
To determine the functional significance of WIP1 overex-
pression, we transiently transfected established medullo-
blastoma cell lines and assayed changes in cell cycle and
apoptosis in response to altered levels of WIP1. The D283 and
Daoy cell lines differ in their basal WIP1 expression and their
TP53 status, providing cell systems for gain-of-function
transfection studies. Genotoxic stress in the form of exposure
to UV irradiation or the chemotherapeutic agent VP-16 sta-
bilized p53 levels and induced phosphorylation of p53 in
D283 and Daoy cells, respectively (Fig. 4A). We examined
the effects of increased constitutive WIP1 by transient trans-
fection with a flag-tagged expression plasmid. Flag-tagged
Table 1 WIP1 amplification is associated with gain of chromosome
17q or i17q in primary medulloblastoma specimens
Specimen Copy number (FISH) Amplification* CNA (CGH)
CEP 17 WIP1 WIP1 Chr 17 status
D283 2–4 4–9 Y i17q
Daoy 4 3 N +17
MCF-7 4 [50 Y **
MB13 2 6–7 Y –17p12-p13,
+17p11.2-
q25
MB1 2–4 5–8 Y i17q
MB3 2–4 3–7 Y i17q
MB14 2–4 2–7 Y +17
MB15 2–4 2–6 Y +17
MB5 2 6 Y i17q
MB2 3–4 6–11 Y i17q
MB6 2 4 N i17q
MB28 2 2 N N/C
MB27 2 2 N N/C
MB4 2–3 2–3 N i17q
FISH analysis for WIP1 and chromosome 17 centromere reveals low-
level amplification of WIP1 in 7 of 11 primary medulloblastoma
samples. WIP1 copy gain is significantly associated with gain of 17q
(P = 0.00057)
*Amplification is defined as [4 copies as determined by FISH
**Reportedly amplified, but not determined in the present study
Abbreviations: MB, medulloblastoma; +17, gain of chromosome 17;
–17, loss of chromosome 17; N/C, no change in chromosome 17;
CNA, copy number aberration; CEP 17, centromeric chromosome 17
probe
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WIP1 could be readily distinguished from endogenous WIP1
on Western blots and WIP1 transfection was accompanied by
decreased phospho-p53 (Ser15) in treated D283 and Daoy
cells that are wild-type and mutant for TP53, respectively
(Fig. 4A).
Determination of RNA levels with qRT-RTPCR con-
firmed significant expression of TP53 and WIP1 by
transfection with WIP1-flag and TP53-GFP expression
plasmids (Fig. 4B). To confirm the transcriptional effects
of WIP1- and TP53-expression plasmids, we co-transfected
cell lines with the p53-responsive p21-luciferase reporter
plasmid and an actin promoter-driven Renilla luciferase
plasmid to control for transfection efficiency. Transfected
WIP1 partially abrogated p53-dependent luminescence
indicating anti-p53 activity in both cell lines in vitro.
Presumably because of endogenous wild-type TP53, the
relative response in D283 cells was less dramatic than in
Daoy cells (Fig. 4C).
VP-16 and constitutively expressed p53 induce
apoptosis
Expression from epitope-tagged plasmids enabled us to
employ flow cytometric methods to analyze the cell cycle
distribution of fluorescently immunolabeled WIP1- and
p53-overexpressing transfectants. To stimulate genotoxic
responses in vitro, we employed minimally toxic dose
Fig. 2 Medulloblastomas with gain of 17q express significantly
higher WIP1 RNA levels. (A) WIP1 RNA expression, by qRT-
RTPCR analysis, is significantly higher in the D283 cell line and in
primary medulloblastoma specimens with gain of 17q or i17q (+17q/
i17q MB, n = 16) by conventional karyotyping and CGH, compared
to Daoy, and primary tumors without i17q or gain of 17q (non-17q
gain MB, n = 17). For reference, expression in the WIP1-amplified
MCF-7 breast cancer cell line is also shown. Columns, mean
expression of at least three experiments; error bars, SEM Y-axis,
RNA expression normalized to GAPDH expression and relative to
human fetal brain. (B) Relative WIP1 RNA expression in individual
medulloblastoma specimens (n = 33) assayed by qRT-RTPCR, and
listed with their associated chromosome 17 status. (C) Relative WIP1
RNA expression in medulloblastomas with WIP1 amplification (open
diamond) is significantly higher than non-amplified tumors (open
circle). Abbreviations: ALL MB, mean (±SEM) of all primary human
tumors; i17q, isochromosome 17q; +17, gain of chromosome 17; –17,
loss of chromosome 17; NC, no change in chromosome 17
J Neurooncol (2008) 86:245–256 251
123
concentrations of etoposide (VP-16), a chemotherapeutic
topoisomerase II-inhibitor used to treat medulloblastoma
clinically. VP-16-induced changes in apoptosis were also
determined by flow cytometric quantitation of cells in sub-
G0/G1 fractions, which were confirmed by TUNEL analysis
(Fig. 4D). Similar results were obtained with micromolar
concentrations of another chemotherapeutic agent, cisplatin
(data not shown).
When exposed to low concentrations of VP-16, the
D283 medulloblastoma cell line underwent increased
apoptosis indicated by an increased fraction of cells in sub-
G0/G1 by flow cytometric analysis, from 4.5 to 17.2%
(P = 0.009) (Fig. 5F). These results indicate that VP-16
induces apoptosis, as described for other cell types with
wild-type p53.
Increasing p53 in D283 cells with a GFP-tagged p53
expression plasmid also increased apoptosis (16.9% in sub-
G0/G1) compared to mock-transfected controls (4.5%,
P = 0.033) (Fig. 5F). VP-16 treatment of p53-transfected
D283 cells further increased the sub-G0/G1 population to
25.6% (P = 0.019 compared to mock-transfected VP-16-
treated controls) (Fig. 5F). These results suggest that
additional constitutive p53 expression in transfected D283
cells can overcome negative regulatory pathways including
endogenous MDM2 and WIP1.
We also transfected the TP53-mutant Daoy medullo-
blastoma cell line. Like wild-type TP53 D283 cells, control
Daoy cells treated with VP-16 increased their apoptotic
sub-G0/G1 population to 20.4 vs. 6% in untreated controls,
suggesting that VP-16 induces apoptosis even in the
absence of wild-type p53 (Fig. 5G). Constitutive expres-
sion of transfected wild-type p53 in TP53-mutant Daoy
cells enhanced VP-16-induced apoptosis to 33.5% (sub-G0/
G1), compared to mock-transfected, VP-16-treated controls
(14.6%, P = 0.044) (Fig. 5G). These data suggest that
transfected p53 expression partially rescues TP53 mutation
in Daoy cells.
WIP1 overexpression limits VP-16- and p53-induced
apoptosis
We examined the effects of constitutive WIP1 expression
in wild-type TP53 D283 cells. VP-16 exposure increased
apoptosis to 18.5 from 5.7% in untreated WIP1-transfected
D283 (Fig. 5F). Despite limited transfection efficiency,
extra WIP1 expression appeared to antagonize p53 activity
even in the absence of genotoxic stress. When D283 cells
were co-transfected to constitutively overexpress both
WIP1 and TP53, they displayed fewer cells in sub-G0/G1
than p53-transfectants (10 vs. 16.9%, respectively;
P = 0.026) (Fig. 5F). These data suggest that additional
WIP1 limits exogenous p53-mediated apoptosis. In double
WIP1- or TP53-transfected D283 cells, VP-16 increased
apoptosis (15%) (Fig. 5F). Compared to VP-16-treated
p53-transfected D283, double transfectants displayed a
trend toward less apoptosis and fewer cells in G0/G1 phase
(Fig. 5F). These data are consistent with anti-p53-induced
apoptosis, presumably due to WIP1 overexpression, despite
genotoxic stimulation.
WIP1-transfected Daoy cells lacking wild-type p53 did
not differ in their cell cycle profile from control trans-
fectants under basal conditions, demonstrating the p53-
dependence of WIP1 effects. However, VP-16-treated
WIP1-transfectants underwent more apoptosis (23.6%)
than untreated counterparts (4.1%) (Fig. 5G). These data
suggest a minimal effect of constitutively expressed
WIP1 in the absence of wild-type p53. Overexpressed
WIP1 also limited p53-mediated apoptosis in doubly co-
transfected Daoy cells. As in controls, VP-16 treatment of
double WIP1/TP53 Daoy transfectants increased cells in
sub-G0/G1 (21.8%) (Fig. 5G). However, VP-16-treated
double WIP1- or TP53-transfectants displayed fewer
apoptotic cells compared to VP-16-treated single p53-
transfectants. Thus, excess WIP1 also appears to protect
VP-16-treated Daoy cells from p53-induced arrest and
apoptosis.
Table 2 WIP1 overexpression is associated with gain of chromo-
some 17q or i17q in primary medulloblastoma specimens
Tumors grouped by CNA n WIP1 RNA P value
+17q MB 3 28.3 0.02*
i17q MB 6 25.4 \0.0001*
+17q or i17q MB 9 26.3 \0.00001*
Non-17q gain MB 2 6.5 –
WIP1 gain/amplification 7 27.7 0.05**
Normal WIP1 copy number 4 14.1 –
Tumors analyzed by FISH (subtotal) 11
+17q MB 5 20.2 0.0533*
i17q MB 11 20.3 \0.0001*
+17q or i17q MB 16 20.3 \0.00001*
Non-17q gain MB 17 5.9 –
All tumors analyzed by CGH (total) 33 13.0 –
WIP1 amplification by FISH was associated with increased WIP1
RNA expression by qRT-RTPCR (P = 0.05). Relative WIP1 RNA
level was significantly associated with gain 17q, including i17q
(P = 0.000001)
*P value: Student t-test of tumors with specified CNA versus tumors
without that CNA
**P value: Student t-test of WIP1-ampllified versus non-amplified
tumors
Abbreviations: MB, medulloblastoma; +17, gain of chromosome 17;
–17, loss of chromosome 17; CNA, copy number aberration
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Discussion
Regulation of the responses of medulloblastoma to geno-
toxic therapies is not well understood. Because TP53 has
been implicated but rarely mutated or deleted in medullo-
blastoma, we focused attention on the candidate oncogene,
WIP1. Recently published studies employed genomic
methods to associate WIP1 with gain of 17q23 in medul-
loblastomas. Mendrzyk et al. used array-CGH to identify
gain of chromosomal region 17q23.2-qter, a locus con-
taining WIP1, in 24 of 47 (51%) medulloblastomas [22].
WIP1 mRNA was moderately overexpressed with respect
to normal cerebellum control in seven of nine tumors.
Immunostaining of a large series of tissue micro-arrays
revealed strong nuclear expression in 148 of 168 (88%)
tumor samples. Ehrbrecht et al. used conventional and
array-CGH to identify amplification of 17q23 in three
(19%) tumors and copy number gain of 17q23 in another 3
out of 16 medulloblastomas [23]. In 3 of 11 (27%) tumors,
WIP1 mRNA was expressed less than fivefold in excess of
expression in normal cerebellum control. Using additional
approaches, we have confirmed gain of the WIP1 locus in
Fig. 3 Medulloblastomas express significant WIP1 protein. (A)
Western blots of cell lines and four primary medulloblastoma
specimens reveal significant WIP1 and p53 protein expression. UV
irradiation (30 J/m2) of D283 increases WIP1 and p53 expression and
induces p53 phosphorylation detected as phospho-p53 (Ser15). Breast
carcinoma cell lines, WIP1-amplified MCF-7 and non-amplified
MCF-10A are shown for reference. Associated chromosome 17
lesions are also labeled. (B) Western analysis of WIP1 protein
expression among primary medulloblastoma specimens (n = 10),
normalized to internal reference b-actin and relative to expression in
the MCF-10A cell line. Abbreviations: all MB, mean (±SEM) of all
primary human tumors (n = 10); i17q, isochromosome 17q; +17, gain
of chromosome 17; –17, loss of chromosome 17; CNA, copy number
aberration
Fig. 4 WIP1 antagonizes p53 activation in medulloblastoma cell
lines. (A) Western blots of D283 and Daoy medulloblastoma cell
lines: Treatment with UV irradiation (UV, 30 J/m2) or etoposide (VP-
16, 1 lM) stabilizes wild-type p53 protein and induces phosphory-
lation of p53 at Ser15. Transfection with the WIP1-flag expression
plasmid detected as higher molecular weight band using anti-WIP1 or
anti-flag antibodies. Overexpressed WIP1 reduces p53 phosphoryla-
tion at serine 15 (Ser15). (B) Increased TP53 and WIP1 RNA in D283
and Daoy cell lines transfected with TP53-GFP and WIP1-flag
(WIP1) expression plasmids compared to the MaxGFP control
plasmid, as measured by qRT-RTPCR. (C) Luciferase assays reveal
that co-transfection of WIP1-flag (WIP1) partially abrogates p53-
dependent transcription from the p21-luciferase reporter (relative to
constitutively expressed control Renilla-luciferase reporter) in TP53-
GFP transfected D283 and Daoy cells (error bars, SEM). (D) TUNEL
assay and flow cytometric methods confirm VP-16-induced apoptosis
in Daoy and D283 cell lines
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medulloblastomas and quantitated its relative overexpres-
sion in our larger series of tumors. These results raise the
possibility that overexpressed WIP1 functions as an
oncoprotein in medulloblastoma.
WIP1 is a p53-dependent gene induced by genotoxic
stress [20, 31]. As a PP2C serine–threonine phosphatase
family member, Wip1 can counteract the tumor suppres-
sive activity of p53 through several distinct mechanisms.
WIP1 dephosphorylates p53 that has been activated in
response to genotoxic stress [21]. WIP1 also dephospho-
rylates and stabilizes MDM2, promoting p53 degradation
(Xiongbin Lu, manuscript submitted). This provides
another feedback loop that returns the cell to a homeostatic
state following DNA repair. Wip1 can complement dif-
ferent oncogenes in their transformation of mouse embryo
fibroblasts. Wip1 overexpression also phenocopies the anti-
apoptotic effects of TP53 mutation in vitro and increases
tumorgenicity in murine models in vivo [20, 32].
Amplification or overexpression of WIP1 in breast and
ovarian cancers may phenocopy the loss of p53 function,
thereby contributing to growth and resistance to genotoxic
therapies [17, 18]. In breast carcinomas with amplified and
overexpressed WIP1, the TP53 locus is rarely mutated,
suggesting that WIP1 amplification inhibits p53 activity
and reduces selection for p53 mutations during tumor
progression [17]. Although WIP1 expression reportedly
correlates with clinical outcomes in patients with breast
and ovarian carcinomas [33, 34], conclusive multivariate
analysis of additional factors (such as the concurrent
deletion of a TP53 allele and loss of 17p seen with i17q)
awaits future analysis of greater tumor numbers.
Analysis of our series of primary medulloblastomas
revealed low-level amplification of WIP1 as well as
increased expression of WIP1 mRNA transcript and
protein, especially in tumors with 17q gain and i17q. The
connection between WIP1 amplification and these common
Fig. 5 WIP1 antagonizes p53-mediated apoptosis and arrest in medul-
loblastoma cell lines. Flow cytometric analysis of cell cycle distributions
of: (A) untreated D283 controls, illustrating the cell populations with 2n
DNA content in G0/G1 phase, 4n DNA content in G2/M phase,
intermediate DNA content in S phase, and the sub-G0/G1 peak
representing apoptotic nuclei; (B) WIP1-flag transfected D283, (C)
p53-GFP transfected D283, (D) WIP1-flag and p53-GFP (WIP1 + p53)
doubly transfected D283, and (E) etoposide (VP-16)-treated D283
(Y-axis, cell number; X-axis, DNA content). Histograms summarizing
flow cytometric analyses of transfected cultures: (F) apoptotic D283 and
(G) apoptotic Daoy in Sub-G0/G1, with plasmids and treatment with
V-16, as indicated (Y-axis, %; X-axis, transfected plasmid(s) and culture
conditions). The following annotation symbols refer to statistically
significant differences in sub-G0/G1 cell populations, as determined by
paired Student t-test: * D283 cells transfected with p53-GFP plasmid
versus mock-transfected D283 cells (P = 0.033). ** D283 cells
co-transfected with both p53-GFP and Flag-WIP1 plasmids versus
D283 cells transfected with p53-GFP alone (P = 0.026). *** D283
cells transfected with p53-GFP plasmid and treated with VP-16 vs.
VP-16-treated, mock-transfected D283 cells (P = 0.019). # D283 cells
transfected with Flag-WIP1 plasmid versus untreated, max-GFP control-
transfected D283 cells (P = 0.013). ## Daoy cells transfected with
p53-GFP plasmid and treated with VP-16 vs. VP-16-treated, mock-
transfected Daoy cells (P = 0.044)
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cytogenetic lesions suggests a selective advantage. Since a
few tumors with i17q did not display WIP1 amplification,
other factors probably contribute to the emergence of this
characteristic cytogenetic lesion. Conversely, one or more
tumors without 17q gain displayed WIP1 overexpression.
Although extra WIP1 copy numbers may explain relative
overexpression via gene dosage effects, regulation at the
post-transcriptional and -translational levels may also
affect WIP1 protein levels. Consistent with our FISH
results, qRT-RTPCR and Western blot analyses demon-
strated increased levels of WIP1 mRNA and protein; both
significantly associated with 17q gain and i17q. The degree
of WIP1 RNA overexpression relative to normal cerebellar
tissue corresponded to earlier reports [22, 23]. The appar-
ent discrepancy between WIP1 expression at the RNA and
protein levels suggests that post-translational modifications
also contribute to WIP1 overexpression. The positive and
negative regulatory networks appear to involve p38MAPK,
MDM2, CHK1, and other DNA damage response factors
[21, 30, 33].
Of note, our analysis was limited to those tumor speci-
mens with available fresh tissue for molecular studies and
displays an unintended selection bias for mixed tumors
with anaplastic features. However, none of our findings
appeared to correlate with histologic subtype or clinical
features. Having confirmed the gain of WIP1 copy numbers
and quantitated its relative overexpression in our medul-
loblastoma series, we hypothesized that overexpressed
WIP1 contributes to treatment resistance by interfering
with p53 function in medulloblastoma.
Because the tumor specimens were obtained before
genotoxic treatment, their WIP1 and p53 levels do not
reflect their activity. Therefore, we employed established
cell lines to analyze the effects of overexpression of WIP1.
Despite their phenotypic differences, D283 and Daoy cells
provide readily manipulable systems for comparing the cell
cycle effects of WIP1 in the setting of wild-type versus
mutant p53. Our results indicate that chemotherapy-
induced genotoxic stress or p53 overexpression alone can
induce apoptosis in D283 cells. The constitutive overex-
pression of p53 overcame endogenous negative regulation
in D283 cells, and rescued TP53-mutation in VP-16-treated
Daoy cells. These results are consistent with studies of
other p53 wild-type cell types, including the neuroepithelial
lineage, indicating that VP-16 induces apoptosis in a
p53-related manner [35–37].
Medulloblastoma cell lines displayed predicted effects
of WIP1 overexpression. In addition to high basal WIP1
levels in D283 cells, additional transfected WIP1 coun-
teracted the apoptotic effects of endogenous p53. The
anti-p53 and chemoprotective effects of overexpressed
WIP1 were also evident upon VP-16 treatment. These
results support the hypothesis that WIP1 overexpression
modulates genotoxic responsiveness by negatively regu-
lating p53 in medulloblastoma cells. WIP1 overexpression
appears to antagonize p53 activation, and provides
medulloblastoma cells the ability to resist arrest and
apoptosis due to genotoxic stress.
The frequency of WIP1 amplification and the degree of
overexpression in primary medulloblastoma strongly sug-
gests the acquisition of selective advantages that may
explain the prevalence of 17q gain and i17q. Based on
evidence from medulloblastoma cell lines , we hypothesize
that WIP1 regulates p53 function, which contributes to
tumor growth and genotoxic treatment resistance. The
recent development and characterization of agents that
inhibit WIP1 raise the possibility of therapeutic interven-
tion in those medulloblastomas with wild-type TP53
[38, 39].
Acknowledgments We thank Darlene G. Skapura, Linda L. Lin,
Diana Joo Youn Hwang, Sowmya Paturi, Jessen A. Rajan, Adekunle
Adesina, Lazlo Perlaky, and Texas Children’s Cancer Center Flow
Cytometry Core Laboratory for technical assistance; Donald L.
Durden for helpful discussions; Ching Lau for supervising tissue
procurement; and Mariano Rocchi for providing the chromosome 17
centromeric clone.This work was supported by funding from:
Stephanie Lee Kramer/American Brain Tumor Association Transla-
tional Grant (Robert C. Castellino); Alex’s Lemonade Stand
Foundation Young Investigator Award (Robert C. Castellino);
Associazione Italiana contro le Leucemie (Massimiliano De Bortoli);
John S. Dunn Research Foundation; NIH Grants HD042977 (Robert
C. Castellino), CA100420 (Lawrence A. Donehower), and NS043517
(John Y. H. Kim); Baylor College of Medicine Collaborative
Research (John Y. H. Kim) and Cancer Center Pilot Grants (Lawrence
A. Donehower, John Y. H. Kim); The Brain Tumor Society (John Y.
H. Kim); John S. McDonnell Foundation (John Y. H. Kim); and John
and Carroll Goodman (John Y. H. Kim). AACR-Aflac, Inc. Career
Development Award for Pediatric Cancer Research (Robert C.
Castellino).
References
1. Giangaspero F, Bigner SH, Giordana MT, Kleihues P, Troja-
nowski JQ (2000) Medulloblastoma. In: Kleihues P, Cavenee
WK (eds) Pathology and genetics: tumours of the nervous sys-
tem. World Health Organization Classification of Tumours.
International Agency for Research of Cancer, Lyon, France,
pp 96–103
2. McNeil DE, Cote TR, Clegg L, Rorke LB (2002) Incidence and
trends in pediatric malignancies medulloblastoma/primitive neu-
roectodermal tumor: a SEER update. Surveillance epidemiology
and end results Med Pediatr Oncol 39:190–194
3. Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of
medulloblastoma: recent advances and future challenges. Semin
Oncol 31:666–675
4. Biegel JA (1999) Cytogenetics and molecular genetics of child-
hood brain tumors. Neuro Oncol 1:139–151
5. Ellison D (2002) Classifying the medulloblastoma: insights from
morphology and molecular genetics. Neuropathol Appl Neurobiol
28:257–282
6. Cogen PH, McDonald JD (1996) Tumor suppressor genes and
medulloblastoma. J Neurooncol 29:103–112
J Neurooncol (2008) 86:245–256 255
123
7. Benard J, Douc-Rasy S, Ahomadegbe JC (2003) TP53 family
members and human cancers. Hum Mutat 21:182–191
8. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW,
Kleihues P (1991) p53 mutations in nonastrocytic human brain
tumors. Cancer Res 51:6202–6205
9. Saylors RL III, Sidransky D, Friedman HS, et al (1991) Infre-
quent p53 gene mutations in medulloblastomas. Cancer Res
51:4721–4723
10. Frank AJ, Hernan R, Hollander A, et al (2004) The TP53-ARF tumor
suppressor pathway is frequently disrupted in large/cell anaplastic
medulloblastoma. Brain Res Mol Brain Res 121:137–140
11. Eberhart CG, Chaudhry A, Daniel RW, Khaki L, Shah KV,
Gravitt PE (2005) Increased p53 immunopositivity in anaplastic
medulloblastoma and supratentorial PNET is not caused by JC
virus. BMC Cancer 5:19
12. Wetmore C, Eberhart DE, Curran T (2001) Loss of p53 but not
ARF accelerates medulloblastoma in mice heterozygous for
patched. Cancer Res 61:513–516
13. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro
hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923
14. Adesina AM, Nalbantoglu J, Cavenee WK (1994) p53 gene
mutation and mdm2 gene amplification are uncommon in
medulloblastoma. Cancer Res 54:5649–5651
15. Batra SK, McLendon RE, Koo JS, et al (1995) Prognostic
implications of chromosome 17p deletions in human medullo-
blastomas. J Neurooncol 24:39–45
16. Giordana MT, Duo D, Gasverde S, et al (2002) MDM2 overex-
pression is associated with short survival in adults with
medulloblastoma. Neuro Oncol 4:115–122
17. Bulavin DV, Demidov ON, Saito S, et al (2002) Amplification of
PPM1D in human tumors abrogates p53 tumor-suppressor
activity. Nat Genet 31:210–215
18. Li J, Yang Y, Peng Y, et al (2002) Oncogenic properties of
PPM1D located within a breast cancer amplification epicenter at
17q23. Nat Genet 31:133–134
19. Saito-Ohara F, Imoto I, Inoue J, et al (2003) PPM1D is a
potential target for 17q gain in neuroblastoma. Cancer Res 63:
1876–1883
20. Bulavin DV, Phillips C, Nannenga B, et al (2004) Inactivation of
the Wip1 phosphatase inhibits mammary tumorigenesis through
p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf)
pathway. Nat Genet 36:343–350
21. Lu X, Nannenga B, Donehower LA (2005) PPM1D dephospho-
rylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes
Dev 19:1162–1174
22. Mendrzyk F, Radlwimmer B, Joos S, et al (2005) Genomic and
protein expression profiling identifies CDK6 as novel indepen-
dent prognostic marker in medulloblastoma. J Clin Oncol
23:8853–8862
23. Ehrbrecht A, Muller U, Wolter M, et al (2006) Comprehensive
genomic analysis of desmoplastic medulloblastomas: identifica-
tion of novel amplified genes and separate evaluation of the
different histological components. J Pathol 208:554–563
24. De Bortoli M, Castellino RC, Lu XY, et al (2006) Medullo-
blastoma outcome is adversely associated with overexpression of
EEF1D, RPL30, and RPS20 on the long arm of chromosome 8.
BMC Cancer 6:223
25. Verma RS, Babu A (eds) (1995) Human chromosomes: principles
and techniques. McGraw-Hill, New York, NY
26. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T,
Kallioniemi A (2006) The serine-threonine protein phosphatase
PPM1D is frequently activated through amplification in aggres-
sive primary breast tumours. Breast Cancer Res Treat 95:
257–263
27. Rao PH, Murty VV, Gaidano G, Hauptschein R, Dalla-Favera R,
Chaganti RS (1994) Subregional mapping of 8 single copy loci to
chromosome 6 by fluorescence in situ hybridization. Cytogenet
Cell Genet 66(4):272–273
28. el-Deiry WS, Tokino T, Velculescu VE, et al (1993) WAF1, a
potential mediator of p53 tumor suppression. Cell 75:817–825
29. Tischer E, Mitchell R, Hartman T, et al (1991) The human gene
for vascular endothelial growth factor. Multiple protein forms are
encoded through alternative exon splicing. J Biol Chem
266:11947–11954
30. Takekawa M, Adachi M, Nakahata A, et al (2000) p53-inducible
wip1 phosphatase mediates a negative feedback regulation of p38
MAPK-p53 signaling in response to UV radiation. EMBO J
19:6517–6526
31. Fiscella M, Zhang H, Fan S, et al (1997) Wip1, a novel human
protein phosphatase that is induced in response to ionizing radi-
ation in a p53-dependent manner. Proc Natl Acad Sci USA
94:6048–6053
32. Demidov ON, Kek C, Shreeram S, et al (2006) The role of the
MKK6/p38 MAPK pathway in Wip1-dependent regulation of
ErbB2-driven mammary gland tumorigenesis. Oncogene 26:
2502–2506
33. Zhang X, Kim J, Ruthazer R, et al (2006) The HBP1 transcrip-
tional repressor participates in RAS-induced premature
senescence. Mol Cell Biol 26:8252–8266
34. Hirasawa A, Saito-Ohara F, Inoue J, et al (2003) Association of
17q21-q24 gain in ovarian clear cell adenocarcinomas with poor
prognosis and identification of PPM1D and APPBP2 as likely
amplification targets. Clin Cancer Res 9:1995–2004
35. Attardi LD, de VA, Jacks T (2004) Activation of the p53-
dependent G1 checkpoint response in mouse embryo fibroblasts
depends on the specific DNA damage inducer. Oncogene 23:
973–980
36. Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in
response to topoisomerase II inhibitors: the role of p53. Cancer
Res 63:4074–4081
37. Nam C, Yamauchi H, Nakayama H, Doi K (2006) Etoposide
induces apoptosis and cell cycle arrest of neuroepithelial cells in a
p53-related manner. Neurotoxicol Teratol 28:664–672
38. Belova GI, Demidov ON, Fornace AJ Jr, Bulavin DV (2005)
Chemical inhibition of Wip1 phosphatase contributes to sup-
pression of tumorigenesis. Cancer Biol Ther 4:1154–1158
39. Yamaguchi H, Durell SR, Feng H, Bai Y, Anderson CW,
Appella E (2006) Development of a substrate-based cyclic
phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Biochemistry 45:13193–13202
256 J Neurooncol (2008) 86:245–256
123
